WARNING : THROMBOSIS , RENAL DYSFUNCTION AND ACUTE RENAL FAILURE • Thrombosis may occur with immune globulin ( IGIV ) products , including ASCENIV .
Risk factors may include : advanced age , prolonged immobilization , hypercoagulable conditions , history of venous or arterial thrombosis , use of estrogens , indwelling central vascular catheters , hyperviscosity , and cardiovascular risk factors .
Thrombosis may occur in the absence of known risk factors ( see Warnings and Precautions [ 5 . 2 ] , Patient Counseling Information [ 17 ] ) .
• Renal dysfunction , acute renal failure , osmotic nephrosis , and death may occur with the administration of IGIV products in predisposed patients .
• Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose .
ASCENIV does not contain sucrose .
• For patients at risk of thrombosis , renal dysfunction or renal failure , administer ASCENIV at the minimum dose and infusion rate practicable .
Ensure adequate hydration in patients before administration .
Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity ( see Dosage and Administration [ 2 . 1 , 2 . 3 ] , Warnings and Precautions [ 5 . 3 ] ) .
WARNING : THROMBOSIS , RENAL DYSFUNCTION AND ACUTE RENAL FAILURE See full prescribing information for complete boxed warning .
• Thrombosis may occur with immune globulin intravenous ( IGIV ) products , including ASCENIV .
Risk factors may include : advanced age , prolonged immobilization , hypercoagulable conditions , history of venous or arterial thrombosis , use of estrogens , indwelling vascular catheters , hyperviscosity , and cardiovascular risk factors .
• Renal dysfunction , acute renal failure , osmotic nephrosis , and death may occur with the administration of IGIV products in predisposed patients .
• Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose .
ASCENIV does not contain sucrose .
[ 5 . 3 ] • For patients at risk of thrombosis , renal dysfunction or renal failure , administer ASCENIV at the minimum dose and infusion rate practicable .
Ensure adequate hydration in patients before administration .
Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity .
[ 2 . 1 , 2 . 3 , 5 . 3 ] 1 INDICATIONS AND USAGE ASCENIV ( immune globulin intravenous , human – slra ) is a 10 % immune globulin liquid for intravenous injection , indicated for the treatment of primary humoral immunodeficiency ( PI ) in adults and adolescents ( 12 to 17 years of age ) .
PI includes , but is not limited to , the humoral immune defect in congenital agammaglobulinemia , common variable immunodeficiency ( CVID ) , X - linked agammaglobulinemia , Wiskott - Aldrich syndrome , and severe combined immunodeficiencies ( SCID ) .
ASCENIV ( immune globulin intravenous , human – slra ) is a 10 % immune globulin liquid for intravenous injection , indicated for the treatment of primary humoral immunodeficiency ( PI ) in adults and adolescents ( 12 to 17 years of age ) .
[ 1 ] 2 DOSAGE AND ADMINISTRATION For intravenous use only .
Dose Initial Infusion Rate Maintenance Infusion Rate ( if tolerated ) 300 - 800 mg / kg every 3 - 4 weeks 0 . 5 mg / kg / min ( 0 . 005 mL / kg / min ) for the first 15 minutes Increase gradually every 15 minutes ( if tolerated ) up to 8 mg / kg / min ( 0 . 08 mL / kg / min ) • Ensure that patients with pre - existing renal insufficiency are not volume depleted ; discontinue ASCENIV if renal function deteriorates .
[ 5 . 3 ] • For patients at risk of renal dysfunction or thrombotic events , administer ASCENIV at the minimum infusion rate practicable .
[ 5 . 2 , 5 . 3 ] 2 . 1 Dose The recommended dose of ASCENIV for replacement therapy in primary humoral immunodeficiency ( PI ) is 300 to 800 mg / kg body weight administered every 3 to 4 weeks .
The dose may be adjusted over time to achieve the desired trough levels and clinical response .
ASCENIV dose adjustments may be required in patients who fail to maintain trough total IgG concentrations of at least 500 mg / dL with a target of 600 mg / dL .
Starting with the second infusion , adjust the dose proportionally , targeting a trough of ≥ 600 mg / dL , based on the previous trough and the associated dose .
For intravenous use only .
Table 1 Dose Initial Infusion Rate Maintenance Infusion Rate ( if tolerated ) 300 - 800 mg / kg every 3 - 4 weeks 0 . 5 mg / kg / min ( 0 . 005 mL / kg / min ) for the first 15 minutes Increase gradually every 15 minutes ( if tolerated ) up to 8 mg / kg / min ( 0 . 08 mL / kg / min ) 2 . 2 Preparation and Handling • ASCENIV is a clear to opalescent , colorless to pale yellow solution .
Inspect visually for particulate matter and discoloration prior to administration .
Do not use if the liquid is cloudy or turbid , or if it contains visible particulate matter .
• Allow refrigerated product to come to room temperature before use and maintain ASCENIV at room temperature during administration .
• DO NOT MICROWAVE .
• DO NOT SHAKE .
• DO NOT MIX with other IGIV products or other intravenous medications .
• DO NOT DILUTE .
• ASCENIV contains no preservatives .
Each vial is for single use only .
Do not reuse or save for future use .
• If large doses are required , several vials may be pooled using aseptic technique into sterile infusion bags and infused .
2 . 3 Administration Begin with an initial infusion rate of 0 . 5 mg / kg / min .
If there are no adverse reactions , the infusion rate for subsequent infusions can be slowly increased to the maximum rate .
Monitor patient vital signs throughout the infusion .
Slow or stop the infusion if adverse reactions occur .
If symptoms subside promptly , the infusion may be resumed at a slower rate which is comfortable for the patient .
Ensure that patients with pre - existing renal insufficiency are not volume - depleted .
For patients judged to be at risk for renal dysfunction or thrombotic events , administer ASCENIV at the minimum infusion rate practicable , and consider discontinuation of administration if renal function deteriorates ( see Boxed Warning , Warnings and Precautions [ 5 . 2 , 5 . 3 ] ) .
3 DOSAGE FORMS AND STRENGTHS ASCENIV is a liquid solution containing 10 % IgG ( 100 mg / mL ) for intravenous infusion .
ASCENIV is a liquid solution containing 10 % IgG ( 100 mg / mL ) for intravenous infusion ; ( 5 g in 50 mL solution ) .
[ 3 ] 4 CONTRAINDICATIONS ASCENIV is contraindicated in : • patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin .
• IgA - deficiency patients with antibodies to IgA and a history of hypersensitivity .
• History of anaphylactic or severe systemic reactions to human immunoglobulin .
[ 4 ] • IgA - deficient patients with antibodies to IgA and a history of hypersensitivity .
[ 4 , 5 . 1 ] 5 WARNINGS AND PRECAUTIONS • IgA - deficient patients with antibodies against IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions .
Have medications such as epinephrine available to treat any acute severe hypersensitivity reactions .
[ 4 , 5 . 1 ] • Thrombotic events have occurred in patients receiving IGIV treatments .
Monitor patients with known risk factors for thrombotic events ; consider baseline assessment of blood viscosity for patients at risk of hyperviscosity .
[ 5 . 2 , 5 . 4 ] • In patients at risk of developing acute renal failure .
monitor renal function , including blood urea nitrogen ( BUN ) , serum creatinine , and urine output .
[ 5 . 3 , 5 . 9 ] • Hyperproteinemia , increased serum viscosity , and hyponatremia or pseudohyponatremia can occur in patients receiving IGIV treatment .
[ 5 . 4 ] • Aseptic meningitis syndrome ( AMS ) has been reported with IGIV treatments , especially with high doses or rapid infusion .
[ 5 . 5 ] • Hemolytic anemia can develop subsequent to IGIV treatment .
Monitor patients for hemolysis and hemolytic anemia .
[ 5 . 6 ] • Monitor patients for pulmonary adverse reactions ( Transfusion - related acute lung injury [ TRALI ] ) .
If transfusion - related acute lung injury is suspected , test the product and patient for antineutrophil antibodies .
[ 5 . 7 ] • Because this product is made from human blood , it may carry a risk of transmitting infectious agents , e . g . , viruses , and theoretically , the Creutzfeldt - Jakob disease ( CJD ) agent .
[ 5 . 8 ] 5 . 1 Hypersensitivity Severe hypersensitivity reactions may occur with IGIV products , including ASCENIV .
In case of hypersensitivity , discontinue ASCENIV infusion immediately and institute appropriate treatment .
Medications such as epinephrine should be available for treatment of acute hypersensitivity reactions .
ASCENIV contains trace amounts of IgA ( ≤ 200 micrograms per milliliter ) ( see Description [ 11 ] ) .
Patients with known antibodies to IgA may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions .
ASCENIV is contraindicated in IgA - deficient patients with antibodies against IgA and a history of hypersensitivity reaction ( see Contraindications [ 4 ] ) .
5 . 2 Thrombosis Thrombosis may occur following treatment with immune globulin products , including ASCENIV .
4 , 5 , 6 Risk factors may include : advanced age , prolonged immobilization , hypercoagulable conditions , history of venous or arterial thrombosis , use of estrogens , indwelling central vascular catheters , hyperviscosity and cardiovascular risk factors .
Thrombosis may occur in the absence of known risk factors .
Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity , including patients with cryoglobulins , fasting chylomicronemia / markedly high triacylglycerols ( triglycerides ) , or monoclonal gammopathies .
For patients at risk of thrombosis , administer ASCENIV at the minimum dose and infusion rate practicable .
Ensure adequate hydration in patients before administration .
Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity ( see Boxed Warning , Dosage and Administration [ 2 ] , Patient Counseling Information [ 17 ] ) .
5 . 3 Acute Renal Dysfunction and Acute Renal Failure Acute renal dysfunction / failure , osmotic nephrosis , and death 1 , 2 may occur upon use of human IGIV products .
Ensure that patients are not volume depleted before administering ASCENIV .
Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk of developing acute renal failure .
2 Assess renal function , including measurement of blood urea nitrogen ( BUN ) and serum creatinine , before the initial infusion of ASCENIV and at appropriate intervals thereafter .
If renal function deteriorates , consider discontinuing ASCENIV ( see Patient Counseling Information [ 17 ] ) .
In patients who are at risk of developing renal dysfunction , because of pre - existing renal insufficiency or predisposition to acute renal failure ( such as diabetes mellitus , hypovolemia , overweight , use of concomitant nephrotoxic medicinal products or age of > 65 years ) , administer ASCENIV at the minimum infusion rate practicable ( see Dosage and Administration [ 2 ] ) .
5 . 4 Hyperproteinemia , Increased Serum Viscosity , and Hyponatremia Hyperproteinemia , increased serum viscosity , and hyponatremia may occur in patients receiving IGIV treatment , including ASCENIV .
It is critical to clinically distinguish true hyponatremia from a pseudohyponatremia that is associated with or causally related to hyperproteinemia with concomitant decreased calculated serum osmolality or elevated osmolar gap , because treatment aimed at decreasing serum free water in patients with pseudohyponatremia may lead to volume depletion , a further increase in serum viscosity , and a possible predisposition to thrombotic events .
3 5 . 5 Aseptic Meningitis Syndrome ( AMS ) AMS may occur with IGIV treatments , including ASCENIV .
AMS usually begins within several hours to 2 days following IGIV treatment .
Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae .
7 , 8 , 9 AMS may occur more frequently in association with high doses ( 2 g / kg ) and / or rapid infusion of IGIV .
AMS is characterized by the following signs and symptoms : severe headache , nuchal rigidity , drowsiness , fever , photophobia , painful eye movements , nausea , and vomiting ( see Patient Counseling Information [ 17 ] ) .
Cerebrospinal fluid ( CSF ) studies frequently reveal pleocytosis up to several thousand cells per cubic millimeter , predominantly from the granulocytic series , and elevated protein levels up to several hundred mg / dL , but negative culture results .
Conduct a thorough neurological examination on patients exhibiting such signs and symptoms , including CSF studies , to rule out other causes of meningitis .
5 . 6 Hemolysis IGIV products , including ASCENIV , may contain blood group antibodies that can act as hemolysins and induce in vivo coating of red blood cells ( RBCs ) with immunoglobulin , causing a positive direct antiglobulin reaction and hemolysis .
10 , 11 , 12 Delayed hemolytic anemia can develop subsequent to IGIV treatment due to enhanced RBC sequestration , 13 and acute hemolysis , consistent with intravascular hemolysis , has been reported .
Monitor patients for clinical signs and symptoms of hemolysis ( see Patient Counseling Information [ 17 ] ) .
If these are present after ASCENIV infusion , perform appropriate confirmatory laboratory testing .
If transfusion is indicated for patients who develop hemolysis with clinically compromising anemia after receiving IGIV , perform adequate cross - matching to avoid exacerbating ongoing hemolysis .
5 . 7 Transfusion - Related Acute Lung Injury ( TRALI ) Noncardiogenic pulmonary edema may occur in patients following IGIV treatment , 14 including ASCENIV .
TRALI is characterized by severe respiratory distress , pulmonary edema , hypoxemia , normal left ventricular function , and fever .
Symptoms typically appear within 1 to 6 hours following treatment .
Monitor patients for pulmonary adverse reactions .
If TRALI is suspected , perform appropriate tests for the presence of anti - neutrophil antibodies in both the product and the patient ’ s serum ( see Patient Counseling Information [ 17 ] ) .
TRALI may be managed using oxygen therapy with adequate ventilatory support .
5 . 8 Transmissible Infectious Agents Because ASCENIV is made from human blood , it may carry a risk of transmitting infectious agents , e . g . , viruses , the variant Creutzfeldt - Jakob disease ( vCJD ) and theoretically , the Creutzfeldt - Jakob disease ( CJD ) agent .
All infections suspected by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to ADMA Biologics at ( 1 - 800 - 458 - 4244 ) .
Before prescribing ASCENIV , the physician should discuss the risks and benefits of its use with the patient ( see Patient Counseling Information [ 17 ] ) .
5 . 9 Monitoring Laboratory Tests • Periodic monitoring of renal function and urine output is particularly important in patients at increased risk of developing acute renal failure .
Assess renal function , including measurement of blood urea nitrogen ( BUN ) and serum creatinine , before the initial infusion of ASCENIV and at appropriate intervals thereafter .
• Because of the potentially increased risk of thrombosis with IGIV treatment , consider baseline assessment of blood viscosity in patients at risk for hyperviscosity , including those with cryoglobulins , fasting chylomicronemia / markedly high triacylglycerols ( triglycerides ) , or monoclonal gammopathies .
• If signs and / or symptoms of hemolysis are present after an infusion of ASCENIV , perform appropriate laboratory testing for confirmation .
• If TRALI is suspected , perform appropriate tests for the presence of anti - neutrophil antibodies in both the product and patient ’ s serum .
5 . 10 Interference with Laboratory Tests After infusion of immunoglobulin , the transitory rise of the various passively transferred antibodies in the patient ’ s blood may yield positive serological testing results , with the potential for misleading interpretation .
Passive transmission of antibodies to erythrocyte antigens ( e . g . , A , B , and D ) may cause a positive direct or indirect antiglobulin ( Coombs ’ ) test .
6 ADVERSE REACTIONS The most common adverse reactions to ASCENIV ( reported in ≥ 5 % of clinical study subjects ) were headache , sinusitis , diarrhea , gastroenteritis viral , nasopharyngitis , upper respiratory tract infection , bronchitis , and nausea .
The most common adverse reactions to ASCENIV ( ≥ 5 % of study subjects ) were headache , sinusitis , diarrhea , gastroenteritis viral , nasopharyngitis , upper respiratory tract infection , bronchitis , and nausea .
[ 6 ] To report SUSPECTED ADVERSE REACTIONS , contact ADMA Biologics at ( 1 - 800 - 458 - 4244 ) or FDA at 1 - 800 - FDA - 1088 or www . fda . gov / medwatch .
6 . 1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions , adverse reaction rates observed in clinical trials cannot be directly compared to rates in the clinical trials of another product and may not reflect the rates observed in clinical practice .
In a multicenter , open - label , non - randomized clinical trial , 59 subjects with PI , on regular IGIV replacement therapy , received doses of ASCENIV ranging from 284 to 1008 mg / kg ( mean dose 505 mg / kg ) every 3 weeks or 4 weeks for up to 12 months ( mean 346 days ; range 36 to 385 days ) ( see Clinical Studies [ 14 ] ) .
The use of pre - medication was discouraged ; however , if after two infusions of ASCENIV subjects required pre - medication ( antipyretic , antihistamine , or antiemetic agent ) for recurrent reactions , they could continue those medications for the duration of the trial .
Of the 793 infusions administered during this trial , only 7 ( 11 . 9 % ) subjects received premedication prior to 7 ( 0 . 9 % ) infusions .
Fifty - eight subjects ( 98 % ) had an adverse reaction during the study .
The proportion of subjects who had at least one adverse reaction was similar for both the 3 - and 4 - week cycles .
The most common adverse reactions observed in this clinical trial were headache ( 22 subjects , 37 % ) , sinusitis ( 16 subjects , 27 % ) , diarrhea ( 14 subjects , 23 % ) , gastroenteritis viral ( 13 subjects , 22 % ) , nasopharyngitis ( 13 subjects , 22 % ) , upper respiratory tract infection ( 13 subjects , 22 % ) , bronchitis ( 12 subjects , 20 % ) , nausea ( 12 subjects , 20 % ) , and acute sinusitis ( 11 subjects , 19 % ) .
Adverse reactions ( ARs ) occurring during or within 72 hours after the end of an infusion are presented in Table 2 .
In this study , the upper bound of the 1 - sided 95 % confidence interval for the proportion of ASCENIV infusions with one or more temporally associated adverse reactions was 16 . 4 % .
The total number of adverse reactions was 158 ( a rate of 0 . 20 ARs per infusion ) .
Table 2 : Adverse Reactions ( ARs ) ( within 72 hours after the end of an ASCENIV infusion ) in ≥ 5 % of SubjectsPreferred Term ( MedDRA v16 . 0 ) Number ( % ) of Subjects ( N = 59 ) Number ( % ) of Infusions ( N = 793 ) Headache 14 ( 24 ) 21 ( 2 . 6 ) Sinusitis 6 ( 10 ) 7 ( 0 . 9 ) Nausea 5 ( 9 ) 5 ( 0 . 6 ) Acute sinusitis 4 ( 7 ) 4 ( 0 . 5 ) Fatigue 4 ( 7 ) 9 ( 1 . 1 ) Muscle spasms 4 ( 7 ) 4 ( 0 . 5 ) Bronchitis 3 ( 5 ) 3 ( 0 . 4 ) Diarrhea 3 ( 5 ) 3 ( 0 . 4 ) Nose Bleed 3 ( 5 ) 4 ( 0 . 5 ) Muscle Pain 3 ( 5 ) 5 ( 0 . 6 ) Oropharyngeal pain 3 ( 5 ) 3 ( 0 . 4 ) Pain in extremity 3 ( 5 ) 3 ( 0 . 4 ) Itching 3 ( 5 ) 3 ( 0 . 4 ) 6 . 2 Postmarketing Experience Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size , it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure .
The following adverse reactions have been identified and reported during the post - approval use of IGIV products : • Respiratory : Apnea , Acute Respiratory Distress Syndrome ( ARDS ) , cyanosis , dyspnea , bronchospasm .
• Cardiovascular : Cardiac arrest , vascular collapse , hypotension .
• Neurological : Coma , loss of consciousness , seizures , tremor .
• Integumentary : Stevens - Johnson syndrome , epidermolysis , erythema multiforme , bullous dermatitis .
• Hematologic : Pancytopenia , leukopenia .
• General / Body as a Whole : Pyrexia , rigors .
• Gastrointestinal : Hepatic dysfunction , abdominal pain .
7 DRUG INTERACTIONS Immunoglobulin administration may transiently impair the efficacy of live attenuated virus vaccines such as measles , mumps , rubella , and varicella because the continued presence of high levels of passively acquired antibody may interfere with an active antibody response .
15 , 16 The immunizing physician should be informed of recent therapy with ASCENIV so that appropriate measures may be taken ( see Patient Counseling Information [ 17 ] ) .
• Passive transfer of antibodies may transiently interfere with the immune response to live virus vaccines , such as measles , mumps , rubella , and varicella .
[ 7 ] • Passive transfer of antibodies may confound the results of serological testing .
[ 5 . 10 ] 8 USE IN SPECIFIC POPULATIONS Geriatric Use : In patients over age 65 or in any patient at risk of developing renal insufficiency , do not exceed the recommended dose , and infuse ASCENIV at the minimum infusion rate practicable .
[ 8 . 5 ] 8 . 1 Pregnancy Risk Summary No human data are available to indicate the presence or absence of drug - associated risk .
Animal reproduction studies have not been conducted with ASCENIV .
It is not known whether ASCENIV can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity .
Immune globulins cross the placenta from maternal circulation increasingly after 30 weeks of gestation .
In the U . S . general population , the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 - 4 % and 15 - 20 % respectively .
ASCENIV should be given to pregnant women only if clearly needed .
17 , 18 8 . 2 Lactation Risk Summary No human data are available to indicate the presence or absence drug - associated risk .
The developmental and health benefits of breast feeding should be considered along with the mother ’ s clinical need for ASCENIV and any potential adverse effects on the breast - fed infant from ASCENIV or from the underlying maternal condition .
8 . 4 Pediatric Use ASCENIV was evaluated in 11 pediatric subjects ( 6 children less than 12 years and 5 adolescents age 12 – 16 years ) with primary humoral immunodeficiency ( PI ) .
The pharmacokinetic ( PK ) , safety , and effectiveness profile of ASCENIV in adolescent subjects appeared to be comparable to that demonstrated in adult subjects .
There are insufficient PK , safety , and effectiveness data from pediatric subjects younger than 12 years .
Safety and effectiveness has not been studied in pediatric patients with PI who are under the age of 3 years ( see Clinical Studies [ 14 ] ) .
8 . 5 Geriatric Use Clinical studies of ASCENIV did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects .
Other reported clinical experience has not identified differences in responses between the elderly and younger patients .
In general , dose selection for an elderly patient should be cautious , usually starting at the low end of the dosing range , reflecting the greater frequency of decreased hepatic , renal , or cardiac function , and of concomitant disease or other drug therapy .
10 OVERDOSAGE With intravenous administration , overdose may lead to fluid overload and hyperviscosity .
Patients at risk of complications of fluid overload and hyperviscosity include elderly patients and those with cardiac or renal impairment .
11 DESCRIPTION ASCENIV is a purified , sterile , ready - to - use preparation of concentrated human immunoglobulin G ( IgG ) antibodies .
The product is a clear to opalescent liquid , which is colorless to pale yellow .
The distribution of IgG subclasses is similar to that of normal plasma .
The active ingredient is human immunoglobulin purified from source human plasma and processed using a modified classical Cohn Method 6 / Oncley Method 9 fractionation procedure .
ASCENIV contains 100 ± 10 mg / mL protein , of which not less than 96 % is human immunoglobulin obtained from source human plasma .
It is formulated in water for injection containing 0 . 100 - 0 . 140 M sodium chloride , 0 . 20 - 0 . 29 M glycine , 0 . 15 – 0 . 25 % polysorbate 80 , with pH 4 . 0 – 4 . 6 .
ASCENIV contains ≤ 200 µg / mL of IgA .
Each plasma donation used for the manufacture of ASCENIV is collected from FDA - licensed facilities .
Plasma donations must test negative for hepatitis B virus ( HBV ) surface antigen ( HBsAg ) , antibodies to human immunodeficiency virus ( HIV ) strains 1 and 2 ( anti - HIV - 1 / 2 ) , and antibodies to the hepatitis C virus ( anti - HCV ) as determined by enzyme immunoassay ( EIA ) .
In addition , each plasma unit must test negative and / or non - reactive for HIV RNA , HCV RNA , HBV DNA , Hepatitis A Virus ( HAV ) RNA , and Parvovirus B19 ( B19 virus ) DNA as determined by Nucleic Acid Amplification Testing ( NAT ) of plasma minipools .
NATs for HIV , HAV , HBV , HCV and B19 virus DNA are also performed on a sample of the manufacturing pool .
The limit for B19 virus DNA in a manufacturing pool is set not to exceed 10 4 IU / mL and all other NAT results must be negative .
The manufacturing process of ASCENIV employs three steps to remove / inactivate adventitious viruses to minimize the risk of virus transmission .
The steps are " Precipitation and removal of fraction III " during cold ethanol fractionation , classical " solvent / detergent treatment " and " 35 nm virus filtration . "
In compliance with current guidelines , the steps have been separately validated in a series of in vitro experiments for their capacity to inactivate or remove both enveloped and nonenveloped viruses .
Precipitation and removal of fraction III removes both enveloped and non - enveloped viruses , solvent / detergent treatment represents a virus inactivation step for enveloped viruses , and 35 nm virus filtration removes both enveloped and non - enveloped viruses by size exclusion .
In addition to the steps above , low pH during several steps of the production process contributes to virus inactivation .
The results of virus validation studies for ASCENIV are shown in Table 3 , expressed as log 10 reduction factors .
Table 3 : Virus Validation Data for ASCENIV * without depth filtration -- not done values below 1 log 10 are considered as insignificant and are not used for total clearance ; HIV , human immunodeficiency virus ; BVDV , Bovine viral diarrhea virus , model virus for HCV ; SinV , Sindbis virus , model virus for HCV ; WNV , West Nile virus ; PRV , Pseudorabies virus , model virus for herpes viruses and Hepatitis B virus ; MEV , Murine encephalomyelitis virus , model virus for hepatitis A virus ; BPV , Bovine parvovirus , model virus for human B19 virus ; PPV , Porcine parvovirus , model virus for human B19 virus ; SV40 , Simian virus 40 , model virus for highly resistant non - enveloped viruses .
Virus Reduction ( log 10 ) Virus Type Family Enveloped Viruses Non - enveloped Viruses Retro Flavi Herpes Parvo Picorna Polyoma Step / Test Virus HIV BVDV SinV WNV PRV PPV BPV MEV SV40 Precipitation and Removal of Fraction III and Depth Filtration - 1 . 87 * - - - 4 . 00 - 5 . 29 2 . 00 * TnBP / Triton X - 100 Treatment > 4 . 43 > 5 . 04 > 7 . 11 > 4 . 96 > 4 . 01 - - - - 35 nm Virus Filtration > 5 . 19 > 4 . 88 - - > 4 . 64 < 1 . 0 6 . 18 < 1 . 0 > 5 . 02 Total Clearance > 9 . 62 > 11 . 79 > 7 . 11 > 4 . 96 > 8 . 65 4 . 00 6 . 18 5 . 29 > 7 . 02 12 CLINICAL PHARMACOLOGY 12 . 1 Mechanism of Action ASCENIV is a replacement therapy for patients with primary humoral immunodeficiency ( PI ) ( e . g . agammaglobulinemia , hypogammaglobulinemia , CVID , SCID ) .
The broad spectrum of neutralizing IgG antibodies against bacterial and viral pathogens and their toxins helps to avoid recurrent serious opportunistic infections .
IgG antibodies are opsonins that increase phagocytosis and elimination of pathogens from the circulation .
The mechanism of action has not been fully elucidated in PI .
12 . 2 Pharmacodynamics ASCENIV contains mainly immunoglobulin G ( IgG ) with a broad spectrum of antibodies against various infectious agents , reflecting the IgG activity found in the donor population .
ASCENIV which is prepared from pooled plasma from not less than 1 , 000 donors , has an IgG subclass distribution similar to that of native human plasma .
Adequate doses of IGIV can restore an abnormally low IgG level to the normal range .
Standard pharmacodynamics studies were not performed .
12 . 3 Pharmacokinetics In a prospective , open - label , single - arm , multicenter clinical study , efficacy , safety and pharmacokinetics of ASCENIV were evaluated in 59 subjects with PI ( See Clinical Studies [ 14 ] ) .
Serum concentrations of total IgG were measured in 30 subjects ( four subjects , ages 7 to 16 years and 26 subjects from 17 to 74 years ) following the seventh infusion for subjects on a 4 - week dosing interval and the ninth infusion for subjects on a 3 - week dosing interval .
The dose of ASCENIV used in these subjects ranged from 291 mg / kg to 760 mg / kg .
After the infusion , blood samples were taken until Day 28 after infusion for the 4 - week dosing interval and until Day 21 after infusion for the 3 - week dosing interval .
Table 4 summarizes the Total IgG Pharmacokinetic Parameters of ASCENIV , based on serum concentration of total IgG .
The mean ± SD half - life of ASCENIV was 28 . 5 ± 4 . 4 days for subjects on a 3 - week dosing interval and 39 . 7 ± 11 . 6 days for subjects on a 4 - week dosing interval for the 30 subjects in the pharmacokinetic subgroup .
Although no systematic study was conducted to evaluate the effect of sex on the pharmacokinetics of ASCENIV , based on the small sample size ( 11 males and 19 females ) the pharmacokinetics of ASCENIV was comparable between males and females .
In adolescents , the pharmacokinetics of ASCENIV was comparable with adults .
There were insufficient PK data in children younger than 12 years .
Table 4 : Total IgG Pharmacokinetic Parameter Estimates ( PK Population ) in SubjectsAUC tau = steady - state area under the plasma concentration versus time curve with tau = dosing interval ; CL = total body clearance ; C max = maximum concentration ; C min = minimum concentration ; CV = coefficient of variation ; n = number of subjects ; NA = not applicable ; SD = standard deviation ; T max = time of maximum concentration ; t ½ = terminal half - life ; V ss = Volume of distribution steady - state ; a median ( range ) 3 - week cycle ( n = 10 ) 4 - week cycle ( n = 20 ) Statistic Mean ( SD ) CV % Mean ( SD ) CV % C max ( mg / dL ) 2 , 427 ( 452 ) 18 . 6 2 , 227 ( 584 ) 26 . 2 C min ( mg / dL ) 1 , 152 ( 308 ) 26 . 7 954 ( 245 ) 25 . 7 T max ( h ) a 2 . 93 ( 1 . 80 , 4 . 52 ) NA 2 . 78 ( 1 . 43 , 99 . 1 ) NA AUC tau ( d * mg / dL ) 32 , 128 ( 7 , 020 ) 21 . 9 35 , 905 ( 9 , 351 ) 26 . 0 t ½ ( d ) 28 . 47 ( 4 . 4 ) 15 . 4 39 . 70 ( 11 . 6 ) 29 . 1 CL ( mL / d / kg ) 1 . 68 ( 0 . 4 ) 25 . 4 1 . 47 ( 0 . 5 ) 33 . 6 V ss ( mL / kg ) 76 . 79 ( 13 . 5 ) 17 . 5 89 . 57 ( 26 . 2 ) 29 . 2 Table 5 : Total IgG Pharmacokinetic Parameter Estimates ( PK Population ) in Subjects — Baseline CorrectedAUC ( 0 - t ) = steady - state area under the plasma concentration versus time curve with 0 - t = dosing interval ; CL = total body clearance ; Cmax = maximum concentration ; Cmin = minimum concentration ; CV = coefficient of variation ; N = number of subjects ; SD = standard deviation ; T max = time of maximum concentration ; t ½ = terminal half - life ; V z = Apparent Volume of distribution during terminal phase ; 3 - week cycle 4 - week cycle Statistic Mean ( SD ) CV % N Mean ( SD ) CV % N C max ( mg / dL ) 1223 ( 297 ) 24 . 2 10 1231 ( 453 ) 37 20 C max ( mg / dL ) 19 ( 31 ) 166 10 46 ( 42 ) 178 20 T max ( h ) 3 . 04 ( 0 . 8 ) 27 10 8 ( 22 ) 282 20 AUC ( 0 - t ) ( d * mg / dL ) 6604 ( 2913 ) 44 10 7936 ( 3482 ) 44 20 t ½ ( d ) 6 ( 2 ) 41 5 10 ( 8 ) 80 9 CL ( mL / d / kg ) 9 ( 4 ) 42 10 8 ( 5 ) 61 20 V z ( mL / kg ) 82 ( 62 ) 75 5 82 ( 35 ) 43 9 13 NONCLINICAL TOXICOLOGY 13 . 1 Carcinogenesis , Mutagenesis , Impairment of Fertility No animal studies were conducted to evaluate the carcinogenic or mutagenic effects of ASCENIV or its effects on fertility .
13 . 2 Animal Toxicology and / or Pharmacology No animal studies were conducted to evaluate possible toxicity of ASCENIV .
ASCENIV contains Polysorbate 80 ; Intravenous administrations of Polysorbate 80 in multiple species have been linked with a decrease in blood pressure .
In rats , single doses of Polysorbate 80 that were up to 25 times higher than the amount from 800 mg / kg ASCENIV resulted in an increase of liver enzymes and total bilirubin .
14 CLINICAL STUDIES A prospective , open - label , single - arm , multicenter trial assessed the efficacy , safety , and pharmacokinetics of ASCENIV in adult and pediatric subjects with PI .
Study subjects were receiving regular IGIV replacement therapy , with a stable dose between 300 and 800 mg / kg for at least 3 months prior to participation in this trial .
Subjects received an ASCENIV infusion administered every 3 or 4 weeks ( both the dose and schedule depending on their prior therapy ) for 12 months .
A total of 59 subjects were enrolled into the trial , 28 men and 31 women with a mean age of 42 years ; 93 % were Caucasian , 5 % were Hispanic and 2 % African American .
Forty - eight subjects were adults ( 81 % ) between 17 and 74 years of age .
There were 11 pediatric subjects ( see Pediatric Use [ 8 . 4 ] ) , and 11 subjects ( 18 . 6 % ) ≥ 65 years of age .
The oldest subject was 74 years of age .
The youngest subject was 3 years of age .
There were 19 subjects with a 3 - week cycle and 40 subjects with a 4 - week cycle .
There were 45 subjects ( 76 % ) with common variable immunodeficiency ( CVID ) as their primary diagnosis , followed by X - linked Agammaglobulinemia ( 10 % ) , Antibody Deficiencies and ‘ Other ’ ( 7 % each ) .
The modified intent - to - treat ( mITT ) population included 59 subjects and was used for efficacy analysis .
The study assessed the efficacy of ASCENIV in preventing serious bacterial infections ( SBIs ) , defined as a rate of < 1 . 0 cases of bacterial pneumonia , bacteremia / septicemia , osteomyelitis / septic arthritis , visceral abscess , and bacterial meningitis per person - year .
Secondary efficacy parameters included time to first SBI and time to first infection of any kind / seriousness , days on antibiotics ( excluding prophylaxis ) , days off school / work due to infections , all confirmed infections of any kind or seriousness , and hospitalizations due to infection .
During the 12 - month study period , zero ( 0 ) serious acute bacterial infections occurred .
Thus , the mean event rate of serious , acute , bacterial infections per year was 0 . 0 ( with an upper 1 - sided 99 % confidence interval of < 1 . 0 per subject year , which met the study ’ s primary efficacy endpoint ) .
Thirty - nine percent ( 39 % ) of subjects had days off work , school or daycare due to an infection .
Of the infections reported , 1 resulted in hospitalization as a post - op local wound infection from elective surgery ( see Table 6 ) .
The incidence and severity of infections in adolescents were similar to those in adult subjects .
Table 6 : Summary of Efficacy Results in Subjects with PISBI = serious bacterial infections .
aPerson - years : Person - time in years with 2 decimals = ( the Final Clinical Visit Date - the Day 0 date + 1 ) / 365 . 25 , where the final clinical visit date is defined as the specimen collection date of the final clinical visit for urinalysis , or the specimen collection date for the clinical laboratory tests at the final clinical visit and Day 0 date is the start date of the first ASCENIV infusion .
b Defined as bacterial pneumonia , bacterial meningitis , bacteremia / septicemia , osteomyelitis / septic arthritis , and visceral abscess .
c The calculation of antibiotic use includes subjects who received antibiotics for therapeutic use .
Number of Subjects ( mITT Population ) Total Number of person - years a 59 55 . 9 Infections Number of confirmed serious acute bacterial infections b Rate of SBIs ( SBIs / total person - years ) Rate of Infections ( Infections / total person - years ) a 0 0 . 0 3 . 4 Antibiotic use due to infection c Number of subjects ( % ) Days per subject per year 37 ( 63 % ) 32 . 9 Days off school / daycare / work due to infection Number of persons with days off of school , daycare or work due to infections Total days Days per subject per year 23 ( 39 % ) 93 1 . 7 Unscheduled Medical Visits due to infection Number of persons with unscheduled medical visits due to infections ( % ) Total visits Visits per subject per year 24 ( 41 % ) 54 0 . 97 Hospitalization due to infection Number of subjects ( % ) Number of Days Hospitalizations per subject per year 1 ( 1 . 7 % ) 5 0 . 02 15 REFERENCES • Gupta N , Ahmed I , Nissel - Horowitz S , Patel D , Mehrotra B . Intravenous gammaglobulin - associated acute renal failure .
Am J Hematol 2001 ; 66 : 151 - 152 .
• Cayco , A . V . , M . A . Perazella , and J . P . Hayslett .
Renal insufficiency after intravenous immune globulin therapy : a report of two cases and an analysis of the literature .
J Am Soc Nephrol 1997 ; 8 : 1788 - 1794 .
• Steinberger BA , Ford SM , Coleman TA .
Intravenous immune globulin therapy results in post - infusional hyperproteinemia , increased serum viscosity , and pseudohyponatremia .
Am J Hematol 2003 ; 73 : 97 - 100 .
• Dalakas MC .
High - dose intravenous immunoglobulin and serum viscosity : risk of precipitating thromboembolic events .
Neurology 1994 ; 44 : 223 - 226 .
• Woodruff RK , Grigg AP , Firkin FC , Smith IL .
Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients .
Lancet 1986 ; 2 : 217 - 218 .
• Wolberg AS , Kon RH , Monroe DM , Hoffman M . Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations .
Am J Hematol 2000 ; 65 : 30 - 34 .
• Casteels - Van Daele , M . , et al .
Intravenous immune globulin and acute aseptic meningitis [ letter ] .
N Engl J Med 1990 ; 323 : 614 - 615 .
• Kato , E . , et al .
Administration of immune globulin associated with aseptic meningitis [ letter ] .
Jama 1988 ; 259 : 3269 - 3271 .
• Scribner , C . L . , et al .
Aseptic meningitis and intravenous immunoglobulin therapy [ editorial , comment ] .
Ann Intern Med 1994 ; 121 : 305 - 306 .
• Copelan EA , Stohm PL , Kennedy MS , Tutschka PJ .
Hemolysis following intravenous immune globulin therapy .
Transfusion 1986 ; 26 : 410 - 412 .
• Thomas MJ , Misbah SA , Chapel HM , Jones M , Elrington G , Newsom - Davis J . Hemolysis after high - dose intravenous Ig .
Blood 1993 ; 15 : 3789 .
• Wilson JR , Bhoopalam N , Fisher M . Hemolytic anemia associated with intravenous immunoglobulin .
Muscle & Nerve 1997 ; 20 : 1142 - 1145 .
• Kessary - Shoham H , Levy Y , Shoenfeld Y , Lorber M , Gershon H .
In vivo administration of intravenous immunoglobulin ( IVIg ) can lead to enhanced er ythrocyte sequestration .
J Autoimmune 1999 ; 13 : 129 - 135 .
• Rizk A , Gorson KC , Kenney L , Weinstein R . Transfusion - related acute lung injury after the infusion of IVIG .
Transfusion 2001 ; 41 : 264 - 268 .
• Siber GA , Werner BG , Halsey NA , et al .
Interference of immune globulin with measles and rubella immunization .
J Pediatr 1993 ; 122 : 204 - 211 .
• Salisbury D , Ramsay M , Noakes K , eds .
Immunisation against infectious disease .
The Stationery Office ( TSO ) , London : UK Department of Health ; 2009 : 426 .
• Hammarstrom L , Smith CIE . Placental transfer of intravenous immunoglobulin .
Lancet 1986 ; 1 : 681 .
• Sidiropoulos D , Herrmann U , Morell A , von Muralt G , Barandun S . Transplacental passage of intravenous immunoglobulin in the last trimester of pregnancy .
J Pediatr 1986 ; 109 : 505 - 508 .
16 HOW SUPPLIED / STORAGE AND HANDLING ASCENIV is supplied in a single - use , tamper - evident vial .
The components used in the packaging for ASCENIV are not made with natural rubber latex .
ASCENIV is supplied in 50 mL size containing 5 grams of protein .
• Store at 2 to 8 ° C ( 36 to 46 ° F ) for up to 36 months from the date of manufacture .
Do not freeze .
• Within the first 24 months of shelf - life , product may be stored up to 4 weeks at ≤ 25 ° C ( 77 ° F ) .
After storage at room temperature product must be used or discarded .
17 PATIENT COUNSELING INFORMATION Instruct patients taking ASCENIV to immediately report symptoms of : • Thrombosis which includes pain and / or swelling of an arm or legs / feet with warmth over the affected area , discoloration of an arm or leg , unexplained shortness of breath , acute chest pain or discomfort that worsens on deep breathing , unexplained rapid pulse , numbness or weakness on one side of the body ( see Warning and Precaution [ 5 . 2 ] ) .
• Acute Renal Dysfunction and Acute Renal Failure which includes decreased urine output , sudden weight gain , fluid retention / edema , and / or shortness of breath .
Such symptoms may suggest kidney damage ( see Boxed Warning , Warnings and Precautions [ 5 . 3 ] ) .
• Aseptic Meningitis Syndrome ( AMS ) which includes severe headache , neck stiffness , drowsiness , fever , sensitivity to light , painful eye movements , nausea and vomiting ( see Warnings and Precautions [ 5 . 5 ] ) .
• Hemolysis which includes fatigue , increased heart rate , yellowing of skin or eyes , dark - colored urine ( see Warnings and Precautions [ 5 . 5 ] ) .
• Transfusion - Related Acute Lung Injury ( TRALI ) which includes trouble breathing , chest pain , blue lips or extremities , fever ( see Warnings and Precautions [ 5 . 7 ] ) Inform patients that ASCENIV : • Is made from human plasma and may contain infectious agents that can cause disease .
While the risk that ASCENIV can transmit an infection has been reduced by screening plasma donors for prior exposure , testing donated plasma , and inactivating or removing certain viruses during manufacturing , patients should report any symptoms that concern them ( see Description [ 11 ] and Warnings and Precautions [ 5 ] ) .
• Can interfere with their immune response to live viral vaccines ( e . g . , measles , mumps , rubella , and varicella ) .
Instruct patients to notify their healthcare professional of this potential interaction when they are receiving vaccinations ( see Drug Interactions [ 7 ] ) .
Manufactured by ADMA Biologics Boca Raton , FL 33487 USA U . S . License No . 2019 RM - 5640 Rev . 000 NDC : 69800 - 0250 - 2 - Vial Label [ MULTIMEDIA ] [ MULTIMEDIA ] NDC : 69800 - 0250 - 1 - Carton Label [ MULTIMEDIA ] [ MULTIMEDIA ]
